-
New Frontiers in Inhalation
Thursday, November 15
8:30 am – 11:00 am
Symposium
ACPE #073-999-07-579-L04
The lung has been used as local drug delivery target for many decades. With the approval of inhaled insulin, Exubera, for Type 1 diabetes, opportunities for advanced formulations and new technologies for pulmonary administration are manifold. The objective of this symposium is to highlight novel strategies for advancing inhalation science. In addition, the bridging between discovery, preclinical assessment and excipient selection of novel products will be highlighted. The delivery strategies for critical care patients will also be discussed.
Moderator
Michael T. Riebe, Ph.D.
Merck and Company, Inc.
Overview of Utilization for Novel Excipients
Paul Mydral, Ph.D.
University of Arizona
Positioning the Pulmonary Delivery Route to Discovery Scientists - Developability and Preformulation Aspects
Sarvajna Dwivedi, Ph.D. (invited)
Nektar
Inhaled Insulin – Next Steps for Exubera
Andy Clark, Ph.D. (invited)
Nektar
Delivery of Inhaled Medications to Ventilated, Critical Care Patients
Dirk VonHollen, Ph.D. (invited)
Respironics